+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Metformin use and survival after colorectal cancer: A population-based cohort study



Metformin use and survival after colorectal cancer: A population-based cohort study



International Journal of Cancer 138(2): 369-379



Preclinical evidence suggests that metformin could delay cancer progression. Previous epidemiological studies however have been limited by small sample sizes and certain time-related biases. This study aimed to investigate whether colorectal cancer patients with type 2 diabetes who were exposed to metformin had reduced cancer-specific mortality. We conducted a retrospective cohort study of 1,197 colorectal cancer patients newly diagnosed from 1998 to 2009 (identified from English cancer registries) with type 2 diabetes (based upon Clinical Practice Research Datalink, CPRD, prescription and diagnosis records). In this cohort 382 colorectal cancer-specific deaths occurred up to 2012 from the Office of National Statistics (ONS) mortality data. Metformin use was identified from CPRD prescription records. Using time-dependent Cox regression models, unadjusted and adjusted hazard ratios (HR) and 95% CIs were calculated for the association between post-diagnostic exposure to metformin and colorectal cancer-specific mortality. Overall, there was no evidence of an association between metformin use and cancer-specific death before or after adjustment for potential confounders (adjusted HR 1.06, 95% CI 0.80, 1.40). In addition, after adjustment for confounders, there was also no evidence of associations between other diabetic medications and cancer-specific mortality including sulfonylureas (HR 1.14, 95% CI 0.86, 1.51), insulin use (HR 1.35, 95% CI 0.95, 1.93) or other anti-diabetic medications including thiazolidinediones (HR 0.73, 95% CI 0.46, 1.14). Similar associations were observed by duration of use and for all-cause mortality. This population-based study, the largest to date, does not support a protective association between metformin and survival in colorectal cancer patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058302978

Download citation: RISBibTeXText

PMID: 26331456

DOI: 10.1002/ijc.29720


Related references

Metformin use and survival from lung cancer: A population-based cohort study. Lung Cancer 94: 35-39, 2016

Survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: A population-based retrospective cohort study. Plos One 13(1): E0191129, 2018

Statin use after colorectal cancer diagnosis and survival: a population-based cohort study. Journal of Clinical Oncology 32(28): 3177-3183, 2014

Digoxin use after diagnosis of colorectal cancer and survival: a population-based cohort study. Cancer Epidemiology, Biomarkers and Prevention 24(11): 1804-1807, 2016

Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study. Bmc Cancer 18(1): 228, 2018

A cohort study of metformin exposure and survival in patients with stage I-III colorectal cancer. Cancer Epidemiology, Biomarkers and Prevention 22(8): 1364-1373, 2013

Role of cyclooxygenase-2 inhibitors in the survival outcome of colorectal cancer patients: A population-based cohort study. Kaohsiung Journal of Medical Sciences 33(6): 308-314, 2018

The impact of comorbidity on survival of Danish colorectal cancer patients from 1995 to 2006--a population-based cohort study. Diseases of the Colon and Rectum 52(1): 71-78, 2009

Statin use and survival in colorectal cancer: Results from a population-based cohort study and an updated systematic review and meta-analysis. Cancer Epidemiology 45: 71-81, 2016

The deterioration of muscle mass and radiodensity is prognostic of poor survival in stage I-III colorectal cancer: a population-based cohort study (C-SCANS). Journal of Cachexia, Sarcopenia and Muscle 9(4): 664-672, 2018

Pre-diagnostic body mass index and weight change in relation to colorectal cancer survival among incident cases from a population-based cohort study. Bmc Cancer 16: 402, 2017

Survival impact of surgical resection of primary tumor in patients with stage IV colorectal cancer: results from a large population-based cohort study. Cancer 120(5): 683-691, 2014

The effect of warfarin therapy on breast, colorectal, lung, and prostate cancer survival: a population-based cohort study using the Clinical Practice Research Datalink. Cancer Causes and Control 26(3): 355-366, 2016

Metformin and survival of people with type 2 diabetes and pleural mesothelioma: A population-based retrospective cohort study. Lung Cancer 99: 194-199, 2017

Clinicopathological Features and Survival Outcomes of Colorectal Cancer in Young Versus Elderly: A Population-Based Cohort Study of SEER 9 Registries Data (1988-2011). Medicine 94(35): E1402, 2016